Global Group A and C Meningococcal Polysaccharide Vaccine Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Group A and C Meningococcal Polysaccharide Vaccine market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Group A and C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and C Meningococcal Polysaccharide Vaccine sales in 2023, providing a comprehensive analysis by region and market sector of projected Group A and C Meningococcal Polysaccharide Vaccine sales for 2024 through 2030. With Group A and C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and C Meningococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Group A and C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Group A and C Meningococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and C Meningococcal Polysaccharide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and C Meningococcal Polysaccharide Vaccine.
United States market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Group A and C Meningococcal Polysaccharide Vaccine players cover Pfizer, Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Royal (Wuxi) Bio-Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Group A and C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Group A and C Meningococcal Polysaccharide Vaccine market?
What factors are driving Group A and C Meningococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Group A and C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does Group A and C Meningococcal Polysaccharide Vaccine break out by Type, by Application?
The global Group A and C Meningococcal Polysaccharide Vaccine market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Group A and C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and C Meningococcal Polysaccharide Vaccine sales in 2023, providing a comprehensive analysis by region and market sector of projected Group A and C Meningococcal Polysaccharide Vaccine sales for 2024 through 2030. With Group A and C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and C Meningococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Group A and C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Group A and C Meningococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and C Meningococcal Polysaccharide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and C Meningococcal Polysaccharide Vaccine.
United States market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Group A and C Meningococcal Polysaccharide Vaccine players cover Pfizer, Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Royal (Wuxi) Bio-Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Group A and C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Polysaccharide Vaccine
- Polysaccharide-protein Conjugate Vaccine
- Hospital
- Centers for Disease Control and Prevention
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Sanofi Pasteur
- GlaxoSmithKline
- Merck & Co.
- Royal (Wuxi) Bio-Pharmaceutical
- Zhifei Biological
- Toyouvax
- Walvax
- AIM Bio
- Lanzhou Institute of Biological Products
- Cansino Biologics
- Chengda Biotechnology
- Sinovac
What is the 10-year outlook for the global Group A and C Meningococcal Polysaccharide Vaccine market?
What factors are driving Group A and C Meningococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Group A and C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does Group A and C Meningococcal Polysaccharide Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Group A and C Meningococcal Polysaccharide Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Group A and C Meningococcal Polysaccharide Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Group A and C Meningococcal Polysaccharide Vaccine Segment by Type
2.2.1 Polysaccharide Vaccine
2.2.2 Polysaccharide-protein Conjugate Vaccine
2.3 Group A and C Meningococcal Polysaccharide Vaccine Sales by Type
2.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Type (2019-2024)
2.4 Group A and C Meningococcal Polysaccharide Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Centers for Disease Control and Prevention
2.4.3 Others
2.5 Group A and C Meningococcal Polysaccharide Vaccine Sales by Application
2.5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
3.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (2019-2024)
3.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Company
3.4 Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Product Location Distribution
3.4.2 Players Group A and C Meningococcal Polysaccharide Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GROUP A AND C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Group A and C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.4 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.5 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.6 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
5 AMERICAS
5.1 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country
5.1.1 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
5.1.2 Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
5.2 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
5.3 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region
6.1.1 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2019-2024)
6.1.2 APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2019-2024)
6.2 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
6.3 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Group A and C Meningococcal Polysaccharide Vaccine by Country
7.1.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
7.1.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
7.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
7.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine by Country
8.1.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
8.3 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Group A and C Meningococcal Polysaccharide Vaccine
10.3 Manufacturing Process Analysis of Group A and C Meningococcal Polysaccharide Vaccine
10.4 Industry Chain Structure of Group A and C Meningococcal Polysaccharide Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
11.3 Group A and C Meningococcal Polysaccharide Vaccine Customer
12 WORLD FORECAST REVIEW FOR GROUP A AND C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
12.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
12.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Region (2025-2030)
12.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Type (2025-2030)
12.7 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Sanofi Pasteur
13.2.1 Sanofi Pasteur Company Information
13.2.2 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Pasteur Main Business Overview
13.2.5 Sanofi Pasteur Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.4.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 Royal (Wuxi) Bio-Pharmaceutical
13.5.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.5.2 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.5.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.5.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.6 Zhifei Biological
13.6.1 Zhifei Biological Company Information
13.6.2 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.6.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Zhifei Biological Main Business Overview
13.6.5 Zhifei Biological Latest Developments
13.7 Toyouvax
13.7.1 Toyouvax Company Information
13.7.2 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.7.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Toyouvax Main Business Overview
13.7.5 Toyouvax Latest Developments
13.8 Walvax
13.8.1 Walvax Company Information
13.8.2 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.8.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Walvax Main Business Overview
13.8.5 Walvax Latest Developments
13.9 AIM Bio
13.9.1 AIM Bio Company Information
13.9.2 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.9.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 AIM Bio Main Business Overview
13.9.5 AIM Bio Latest Developments
13.10 Lanzhou Institute of Biological Products
13.10.1 Lanzhou Institute of Biological Products Company Information
13.10.2 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.10.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Lanzhou Institute of Biological Products Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Latest Developments
13.11 Cansino Biologics
13.11.1 Cansino Biologics Company Information
13.11.2 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.11.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Cansino Biologics Main Business Overview
13.11.5 Cansino Biologics Latest Developments
13.12 Chengda Biotechnology
13.12.1 Chengda Biotechnology Company Information
13.12.2 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.12.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Chengda Biotechnology Main Business Overview
13.12.5 Chengda Biotechnology Latest Developments
13.13 Sinovac
13.13.1 Sinovac Company Information
13.13.2 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.13.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Sinovac Main Business Overview
13.13.5 Sinovac Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Group A and C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Group A and C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Polysaccharide Vaccine
Table 4. Major Players of Polysaccharide-protein Conjugate Vaccine
Table 5. Global Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 6. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Table 7. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue byType (2019-2024) & ($ million)
Table 8. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share byType (2019-2024)
Table 9. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Group A and C Meningococcal Polysaccharide Vaccine Sale by Application (2019-2024) & (Dose)
Table 11. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2019-2024)
Table 12. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2019-2024) & ($ million)
Table 13. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2019-2024)
Table 14. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Company (2019-2024) & (Dose)
Table 16. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2019-2024)
Table 17. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2019-2024)
Table 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Producing Area Distribution and Sales Area
Table 21. Players Group A and C Meningococcal Polysaccharide Vaccine Products Offered
Table 22. Group A and C Meningococcal Polysaccharide Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2019-2024) & (Dose)
Table 26. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share Geographic Region (2019-2024)
Table 27. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country/Region (2019-2024) & (Dose)
Table 30. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2019-2024)
Table 31. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 34. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2019-2024)
Table 35. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 37. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 38. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2019-2024) & (Dose)
Table 39. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2019-2024)
Table 40. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 42. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 43. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 44. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 46. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 47. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 48. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 50. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 51. Key Market Drivers & Growth Opportunities of Group A and C Meningococcal Polysaccharide Vaccine
Table 52. Key Market Challenges & Risks of Group A and C Meningococcal Polysaccharide Vaccine
Table 53. Key IndustryTrends of Group A and C Meningococcal Polysaccharide Vaccine
Table 54. Group A and C Meningococcal Polysaccharide Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Group A and C Meningococcal Polysaccharide Vaccine Distributors List
Table 57. Group A and C Meningococcal Polysaccharide Vaccine Customer List
Table 58. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Region (2025-2030) & (Dose)
Table 59. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 61. Americas Group A and C Meningococcal Polysaccharide Vaccine Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Region (2025-2030) & (Dose)
Table 63. APAC Group A and C Meningococcal Polysaccharide Vaccine Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 65. Europe Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 67. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast byType (2025-2030) & (Dose)
Table 69. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Application (2025-2030) & (Dose)
Table 71. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Pfizer Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 74. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Sanofi Pasteur Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 79. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Sanofi Pasteur Main Business
Table 81. Sanofi Pasteur Latest Developments
Table 82. GlaxoSmithKline Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 84. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. GlaxoSmithKline Main Business
Table 86. GlaxoSmithKline Latest Developments
Table 87. Merck & Co. Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 89. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Merck & Co. Main Business
Table 91. Merck & Co. Latest Developments
Table 92. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 94. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 96. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 97. Zhifei Biological Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 99. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Zhifei Biological Main Business
Table 101. Zhifei Biological Latest Developments
Table 102.Toyouvax Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103.Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 104.Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105.Toyouvax Main Business
Table 106.Toyouvax Latest Developments
Table 107. Walvax Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 109. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. Walvax Main Business
Table 111. Walvax Latest Developments
Table 112. AIM Bio Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 114. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. AIM Bio Main Business
Table 116. AIM Bio Latest Developments
Table 117. Lanzhou Institute of Biological Products Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 119. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. Lanzhou Institute of Biological Products Main Business
Table 121. Lanzhou Institute of Biological Products Latest Developments
Table 122. Cansino Biologics Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 124. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. Cansino Biologics Main Business
Table 126. Cansino Biologics Latest Developments
Table 127. Chengda Biotechnology Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 129. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Chengda Biotechnology Main Business
Table 131. Chengda Biotechnology Latest Developments
Table 132. Sinovac Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 134. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 135. Sinovac Main Business
Table 136. Sinovac Latest Developments
LIST OFFIGURES
Figure 1. Picture of Group A and C Meningococcal Polysaccharide Vaccine
Figure 2. Group A and C Meningococcal Polysaccharide Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate 2019-2030 (Dose)
Figure 7. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Group A and C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2023)
Figure 10. Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Polysaccharide Vaccine
Figure 12. Product Picture of Polysaccharide-protein Conjugate Vaccine
Figure 13. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType in 2023
Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share byType (2019-2024)
Figure 15. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Hospital
Figure 16. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Hospital (2019-2024) & (Dose)
Figure 17. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Centers for Disease Control and Prevention
Figure 18. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Centers for Disease Control and Prevention (2019-2024) & (Dose)
Figure 19. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Others
Figure 20. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Others (2019-2024) & (Dose)
Figure 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2023)
Figure 22. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application in 2023
Figure 23. Group A and C Meningococcal Polysaccharide Vaccine Sales by Company in 2023 (Dose)
Figure 24. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company in 2023
Figure 25. Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company in 2023 ($ millions)
Figure 26. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company in 2023
Figure 27. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 30. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 31. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 32. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 33. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 34. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 36. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 37. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2023
Figure 38. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Figure 39. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 40. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 41. United States Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region in 2023
Figure 46. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2019-2024)
Figure 47. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 48. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 49. China Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 53. India Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2023
Figure 57. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Figure 58. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 59. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 60. Germany Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 61.France Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 68. Egypt Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Group A and C Meningococcal Polysaccharide Vaccine in 2023
Figure 74. Manufacturing Process Analysis of Group A and C Meningococcal Polysaccharide Vaccine
Figure 75. Industry Chain Structure of Group A and C Meningococcal Polysaccharide Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Group A and C Meningococcal Polysaccharide Vaccine Sales MarketForecast by Region (2025-2030)
Figure 78. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Group A and C Meningococcal Polysaccharide Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Group A and C Meningococcal Polysaccharide Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Group A and C Meningococcal Polysaccharide Vaccine Segment by Type
2.2.1 Polysaccharide Vaccine
2.2.2 Polysaccharide-protein Conjugate Vaccine
2.3 Group A and C Meningococcal Polysaccharide Vaccine Sales by Type
2.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Type (2019-2024)
2.4 Group A and C Meningococcal Polysaccharide Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Centers for Disease Control and Prevention
2.4.3 Others
2.5 Group A and C Meningococcal Polysaccharide Vaccine Sales by Application
2.5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
3.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (2019-2024)
3.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Company
3.4 Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Product Location Distribution
3.4.2 Players Group A and C Meningococcal Polysaccharide Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GROUP A AND C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Group A and C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.4 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.5 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
4.6 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Growth
5 AMERICAS
5.1 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country
5.1.1 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
5.1.2 Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
5.2 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
5.3 Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region
6.1.1 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2019-2024)
6.1.2 APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2019-2024)
6.2 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
6.3 APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Group A and C Meningococcal Polysaccharide Vaccine by Country
7.1.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
7.1.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
7.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
7.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine by Country
8.1.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2019-2024)
8.3 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Group A and C Meningococcal Polysaccharide Vaccine
10.3 Manufacturing Process Analysis of Group A and C Meningococcal Polysaccharide Vaccine
10.4 Industry Chain Structure of Group A and C Meningococcal Polysaccharide Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
11.3 Group A and C Meningococcal Polysaccharide Vaccine Customer
12 WORLD FORECAST REVIEW FOR GROUP A AND C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
12.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
12.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Region (2025-2030)
12.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Type (2025-2030)
12.7 Global Group A and C Meningococcal Polysaccharide Vaccine Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Sanofi Pasteur
13.2.1 Sanofi Pasteur Company Information
13.2.2 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Pasteur Main Business Overview
13.2.5 Sanofi Pasteur Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.4.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 Royal (Wuxi) Bio-Pharmaceutical
13.5.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.5.2 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.5.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.5.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.6 Zhifei Biological
13.6.1 Zhifei Biological Company Information
13.6.2 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.6.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Zhifei Biological Main Business Overview
13.6.5 Zhifei Biological Latest Developments
13.7 Toyouvax
13.7.1 Toyouvax Company Information
13.7.2 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.7.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Toyouvax Main Business Overview
13.7.5 Toyouvax Latest Developments
13.8 Walvax
13.8.1 Walvax Company Information
13.8.2 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.8.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Walvax Main Business Overview
13.8.5 Walvax Latest Developments
13.9 AIM Bio
13.9.1 AIM Bio Company Information
13.9.2 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.9.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 AIM Bio Main Business Overview
13.9.5 AIM Bio Latest Developments
13.10 Lanzhou Institute of Biological Products
13.10.1 Lanzhou Institute of Biological Products Company Information
13.10.2 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.10.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Lanzhou Institute of Biological Products Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Latest Developments
13.11 Cansino Biologics
13.11.1 Cansino Biologics Company Information
13.11.2 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.11.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Cansino Biologics Main Business Overview
13.11.5 Cansino Biologics Latest Developments
13.12 Chengda Biotechnology
13.12.1 Chengda Biotechnology Company Information
13.12.2 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.12.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Chengda Biotechnology Main Business Overview
13.12.5 Chengda Biotechnology Latest Developments
13.13 Sinovac
13.13.1 Sinovac Company Information
13.13.2 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.13.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Sinovac Main Business Overview
13.13.5 Sinovac Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Group A and C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Group A and C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Polysaccharide Vaccine
Table 4. Major Players of Polysaccharide-protein Conjugate Vaccine
Table 5. Global Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 6. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Table 7. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue byType (2019-2024) & ($ million)
Table 8. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share byType (2019-2024)
Table 9. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Group A and C Meningococcal Polysaccharide Vaccine Sale by Application (2019-2024) & (Dose)
Table 11. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2019-2024)
Table 12. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2019-2024) & ($ million)
Table 13. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2019-2024)
Table 14. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Company (2019-2024) & (Dose)
Table 16. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2019-2024)
Table 17. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2019-2024)
Table 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Group A and C Meningococcal Polysaccharide Vaccine Producing Area Distribution and Sales Area
Table 21. Players Group A and C Meningococcal Polysaccharide Vaccine Products Offered
Table 22. Group A and C Meningococcal Polysaccharide Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2019-2024) & (Dose)
Table 26. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share Geographic Region (2019-2024)
Table 27. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Country/Region (2019-2024) & (Dose)
Table 30. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2019-2024)
Table 31. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 34. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2019-2024)
Table 35. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 37. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 38. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2019-2024) & (Dose)
Table 39. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2019-2024)
Table 40. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 42. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 43. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 44. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 46. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 47. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2019-2024) & (Dose)
Table 48. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales byType (2019-2024) & (Dose)
Table 50. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2019-2024) & (Dose)
Table 51. Key Market Drivers & Growth Opportunities of Group A and C Meningococcal Polysaccharide Vaccine
Table 52. Key Market Challenges & Risks of Group A and C Meningococcal Polysaccharide Vaccine
Table 53. Key IndustryTrends of Group A and C Meningococcal Polysaccharide Vaccine
Table 54. Group A and C Meningococcal Polysaccharide Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Group A and C Meningococcal Polysaccharide Vaccine Distributors List
Table 57. Group A and C Meningococcal Polysaccharide Vaccine Customer List
Table 58. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Region (2025-2030) & (Dose)
Table 59. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 61. Americas Group A and C Meningococcal Polysaccharide Vaccine Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Region (2025-2030) & (Dose)
Table 63. APAC Group A and C Meningococcal Polysaccharide Vaccine Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 65. Europe Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Country (2025-2030) & (Dose)
Table 67. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast byType (2025-2030) & (Dose)
Table 69. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Group A and C Meningococcal Polysaccharide Vaccine SalesForecast by Application (2025-2030) & (Dose)
Table 71. Global Group A and C Meningococcal Polysaccharide Vaccine RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Pfizer Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 74. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Sanofi Pasteur Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 79. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Sanofi Pasteur Main Business
Table 81. Sanofi Pasteur Latest Developments
Table 82. GlaxoSmithKline Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 84. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. GlaxoSmithKline Main Business
Table 86. GlaxoSmithKline Latest Developments
Table 87. Merck & Co. Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 89. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Merck & Co. Main Business
Table 91. Merck & Co. Latest Developments
Table 92. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 94. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 96. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 97. Zhifei Biological Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 99. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Zhifei Biological Main Business
Table 101. Zhifei Biological Latest Developments
Table 102.Toyouvax Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103.Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 104.Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105.Toyouvax Main Business
Table 106.Toyouvax Latest Developments
Table 107. Walvax Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 109. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. Walvax Main Business
Table 111. Walvax Latest Developments
Table 112. AIM Bio Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 114. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. AIM Bio Main Business
Table 116. AIM Bio Latest Developments
Table 117. Lanzhou Institute of Biological Products Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 119. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. Lanzhou Institute of Biological Products Main Business
Table 121. Lanzhou Institute of Biological Products Latest Developments
Table 122. Cansino Biologics Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 124. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. Cansino Biologics Main Business
Table 126. Cansino Biologics Latest Developments
Table 127. Chengda Biotechnology Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 129. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Chengda Biotechnology Main Business
Table 131. Chengda Biotechnology Latest Developments
Table 132. Sinovac Basic Information, Group A and C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 134. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 135. Sinovac Main Business
Table 136. Sinovac Latest Developments
LIST OFFIGURES
Figure 1. Picture of Group A and C Meningococcal Polysaccharide Vaccine
Figure 2. Group A and C Meningococcal Polysaccharide Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate 2019-2030 (Dose)
Figure 7. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Group A and C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2023)
Figure 10. Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Polysaccharide Vaccine
Figure 12. Product Picture of Polysaccharide-protein Conjugate Vaccine
Figure 13. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType in 2023
Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share byType (2019-2024)
Figure 15. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Hospital
Figure 16. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Hospital (2019-2024) & (Dose)
Figure 17. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Centers for Disease Control and Prevention
Figure 18. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Centers for Disease Control and Prevention (2019-2024) & (Dose)
Figure 19. Group A and C Meningococcal Polysaccharide Vaccine Consumed in Others
Figure 20. Global Group A and C Meningococcal Polysaccharide Vaccine Market: Others (2019-2024) & (Dose)
Figure 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2023)
Figure 22. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application in 2023
Figure 23. Group A and C Meningococcal Polysaccharide Vaccine Sales by Company in 2023 (Dose)
Figure 24. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Company in 2023
Figure 25. Group A and C Meningococcal Polysaccharide Vaccine Revenue by Company in 2023 ($ millions)
Figure 26. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company in 2023
Figure 27. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 30. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 31. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 32. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 33. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 34. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales 2019-2024 (Dose)
Figure 36. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue 2019-2024 ($ millions)
Figure 37. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2023
Figure 38. Americas Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Figure 39. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 40. Americas Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 41. United States Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region in 2023
Figure 46. APAC Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2019-2024)
Figure 47. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 48. APAC Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 49. China Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 53. India Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2023
Figure 57. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2019-2024)
Figure 58. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 59. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 60. Germany Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 61.France Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2024)
Figure 68. Egypt Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Group A and C Meningococcal Polysaccharide Vaccine Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Group A and C Meningococcal Polysaccharide Vaccine in 2023
Figure 74. Manufacturing Process Analysis of Group A and C Meningococcal Polysaccharide Vaccine
Figure 75. Industry Chain Structure of Group A and C Meningococcal Polysaccharide Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Group A and C Meningococcal Polysaccharide Vaccine Sales MarketForecast by Region (2025-2030)
Figure 78. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market ShareForecast by Application (2025-2030)
